Kingswood Wealth Advisors LLC Sells 368 Shares of Illumina, Inc. $ILMN

Kingswood Wealth Advisors LLC lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.8% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 3,810 shares of the life sciences company’s stock after selling 368 shares during the period. Kingswood Wealth Advisors LLC’s holdings in Illumina were worth $364,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Rise Advisors LLC lifted its position in shares of Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after buying an additional 224 shares during the period. Rakuten Securities Inc. raised its position in Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock valued at $29,000 after purchasing an additional 270 shares during the last quarter. Center for Financial Planning Inc. bought a new position in Illumina in the 1st quarter valued at $33,000. Golden State Wealth Management LLC raised its position in Illumina by 123.2% in the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock valued at $42,000 after purchasing an additional 292 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its position in Illumina by 2,936.8% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock valued at $46,000 after purchasing an additional 558 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 2.7%

NASDAQ ILMN opened at $93.86 on Friday. The stock has a 50-day simple moving average of $98.33 and a 200 day simple moving average of $90.21. The company has a market capitalization of $14.43 billion, a PE ratio of 11.88, a P/E/G ratio of 2.33 and a beta of 1.40. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm’s revenue was down 4.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ILMN shares. Barclays boosted their target price on Illumina from $90.00 to $95.00 and gave the stock an “underweight” rating in a research report on Thursday, October 2nd. Wall Street Zen downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Royal Bank Of Canada set a $124.00 target price on Illumina in a research report on Tuesday, September 2nd. Canaccord Genuity Group boosted their target price on Illumina from $99.00 to $105.00 and gave the stock a “hold” rating in a research report on Friday, August 1st. Finally, Morgan Stanley boosted their target price on Illumina from $100.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Monday, August 4th. Six analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $123.56.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.